Internship
Intern – Biology Technologies
Posted on 11/12/2024
Cytokinetics
501-1,000 employees
Develops drugs for muscle function improvement
Compensation Overview
$22 - $45Hourly
San Bruno, CA, USA
This is a paid internship at the South San Francisco headquarters for approximately 12 weeks beginning in late May/early June.
You match the following Cytokinetics's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Currently enrolled in a college program with science related major
- Coursework in biology/biochemistry/lab courses or have lab experience
- Experience with mammalian cell culture preferred
- Must be detail oriented and have a proactive attitude in support of research activities and running assays
- Highly focused, organized and motivated team player with good time management skills
- Excellent communication skills and the ability to troubleshoot problems with team members
- Experience in data analysis and/or presentation
- Work on and learn about preclinical drug discovery projects in the areas of muscle biology and metabolism
- Be involved in developing and performing cellular and biochemical assays to determine potency and function of small molecule compounds
- Utilize automated liquid handling to perform high-throughput screening
- Perform molecular biology techniques and utilize lab instrumentation
- Analyze scientific data, maintaining lab notebook records and data presentation
- Experience with mammalian cell culture preferred
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$58.4M
Headquarters
South San Francisco, California
Founded
1998
Simplify's Take
What believers are saying
- Recent investments indicate strong interest in muscle activators and inhibitors.
- Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
- Significant funding from Royalty Pharma supports commercial launch and R&D advancements.
What critics are saying
- Increased competition could impact market share and profitability.
- Potential delays in clinical trials could hinder drug commercialization.
- Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.
What makes Cytokinetics unique
- Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
- The company has a robust pipeline including omecamtiv mecarbil and aficamten.
- Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -5%2 year growth
↓ -2%Setting the stage for its first consumer product after 25 years as a biopharma development company, Cytokinetics has launched "HCM Beyond the Heart," an awareness campaign educating cardiologists and other healthcare professionals (HCP) about the personal burdens caused by hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death.
Cytokinetics prices public offering at $51/share, expected to raise $500M. Offering closes May 28, 2024, with J.P. Morgan, Goldman Sachs, Morgan Stanley as managers.
Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.
Intech Investment Management LLC invests $1.73 million in Cytokinetics, Incorporated (NASDAQ:CYTK).
Under the deal, Cytokinetics will receive $50M for the commercial launch
Bridger Management LLC makes new $1.88 million investment in Cytokinetics, Incorporated (NASDAQ:CYTK).
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.
Armistice Capital has invested in Cytokinetics Incorporated, a late-stage biopharmaceutical organization investigating treatments for impaired muscle function-related cardiovascular and neuromuscular diseases.
Royalty Pharma and Cytokinetics have expanded their strategic funding collaboration, totaling up to $575 million, to support the commercial launch of aficamten and advance Cytokinetics' cardiovascular R&D pipeline. The deal includes immediate $250 million funding, with additional options tied to clinical and regulatory milestones. Key elements include $50 million for commercial launch, $100 million for a Phase 3 trial, $50 million for a Phase 2 trial, and a $50 million equity purchase by Royalty Pharma.
Development funding: Cytokinetics will receive $100 million in upfront capital to fund a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure and reduced ejection fraction.